Rash severity and dose in phase I dose escalation cetuximab (C225) trial

14573 Background: C225 is a monoclonal antibody targeting epidermal growth factor receptor (EGFR). The FDA-approved dose is 400 mg/m2 loading with weekly maintenance at 250 mg/m2. C225 efficacy has...